Maravai Lifesciences Holdings (MRVI) Amortization of Deferred Charges (2020 - 2026)

Maravai Lifesciences Holdings' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 26.57% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 89.19% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 80.5% from the prior year.
• Amortization of Deferred Charges advanced to $1.6 million in Q1 2026 per MRVI's latest filing, from -$5.0 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $3.5 million in Q2 2024 and bottomed at -$5.0 million in Q4 2025.
• The 5-year median for Amortization of Deferred Charges is $1.6 million (2026), against an average of $1.0 million.
• Across the five-year window, Amortization of Deferred Charges surged 204.83% in 2024 and slumped 332.67% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $654000.0 in 2022, then climbed by 13.61% to $743000.0 in 2023, then soared by 190.44% to $2.2 million in 2024, then slumped by 332.67% to -$5.0 million in 2025, then soared by 131.99% to $1.6 million in 2026.
• Per Business Quant, the three latest MRVI Amortization of Deferred Charges figures stand at $1.6 million (Q1 2026), -$5.0 million (Q4 2025), and $2.3 million (Q3 2025).